

ASX RELEASE

10 July 2018

Securities to be released from Escrow

Noxopharm Limited (ASX: NOX) releases the following advice in accordance with ASX Listing Rule 3.10A in relation to securities due for release from escrow.

A total of 46,885,465 ordinary shares are due for release from ASX imposed escrow on **8 August 2018**.

Noxopharm has renewed on a voluntary basis the escrow arrangements relating to 31,027,568 ordinary shares, representing 66.17% of this class of escrowed shares, and 12,075,000 options representing 63.72% of this class of escrowed options, held in the name of Milligene Pty Ltd until **8 May 2019**.

Security Description	Ordinary Shares	Unlisted Options, exercise price \$0.30 expiring 28 February 2021
Total number of Securities in escrow class	46,885,465	18,950,358
Securities extended under Voluntary Escrow until 8 May 2019	(31,027,568)	(12,075,000)
Total number of Securities in escrow class to be released from escrow	15,857,897	(6,875,358)

The aforesaid 15,857,897 Ordinary Shares totaling being released from escrow (representing approximately 13.01% of the Company's shares) are currently not quoted on the ASX and as such quotation of these shares will be sought in accordance with ASX Listing Rule 2.8.2.

David Franks
P: +61 2 9299 9690
E: dfranks@fa.com.au

ABOUT NOXOPHARM LIMITED

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to sensitise cancer cells to radiotherapy and chemotherapy. NOX66 is the first pipeline product.